
Sebastian Oltean

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1384769/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer Research, 2011, 9, 997-1007.	3.4	586
2	Hallmarks of alternative splicing in cancer. Oncogene, 2014, 33, 5311-5318.	5.9	569
3	WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing. Cancer Cell, 2011, 20, 768-780.	16.8	216
4	Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene, 2015, 34, 4311-4319.	5.9	122
5	Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 1889-1904.	6.1	112
6	Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14116-14121.	7.1	104
7	Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. British Journal of Cancer, 2014, 111, 477-485.	6.4	97
8	The anti-angiogenic isoforms of VEGF in health and disease. Biochemical Society Transactions, 2009, 37, 1207-1213.	3.4	96
9	Targeting Angiogenesis in Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 2676.	4.1	94
10	Modulation of the Apoptosis Gene Bcl-x Function Through Alternative Splicing. Frontiers in Genetics, 2019, 10, 804.	2.3	83
11	Alternative splicing of TIAâ€1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Molecular Oncology, 2015, 9, 167-178.	4.6	76
12	Pharmacology of Modulators of Alternative Splicing. Pharmacological Reviews, 2017, 69, 63-79.	16.0	72
13	The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget, 2015, 6, 34358-34374.	1.8	68
14	Alternative Splicing in Angiogenesis. International Journal of Molecular Sciences, 2019, 20, 2067.	4.1	68
15	Differential Expression of VEGF-A _{xxx} Isoforms Is Critical for Development of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 479-493.	5.6	58
16	Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. ELife, 2019, 8, .	6.0	56
17	Nutritional Modulation of Gene Expression and Homocysteine Utilization by Vitamin B12. Journal of Biological Chemistry, 2003, 278, 20778-20784.	3.4	53
18	Detection of VEGF-Axxxb Isoforms in Human Tissues. PLoS ONE, 2013, 8, e68399.	2.5	49

SEBASTIAN OLTEAN

#	Article	IF	CITATIONS
19	SRPK1 inhibition <i>in vivo</i> : modulation of VEGF splicing and potential treatment for multiple diseases. Biochemical Society Transactions, 2012, 40, 831-835.	3.4	45
20	The many faces of SRPK1. Journal of Pathology, 2017, 241, 437-440.	4.5	40
21	Overexpression of VEGF165b in Podocytes Reduces Glomerular Permeability. Journal of the American Society of Nephrology: JASN, 2010, 21, 1498-1509.	6.1	39
22	A B12-responsive Internal Ribosome Entry Site (IRES) Element in Human Methionine Synthase. Journal of Biological Chemistry, 2005, 280, 32662-32668.	3.4	37
23	Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. Journal of Clinical Pathology, 2016, 69, 171-175.	2.0	36
24	A protocol for imaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice. Nature Protocols, 2007, 2, 2166-2181.	12.0	35
25	The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis. Cancer Letters, 2017, 403, 74-85.	7.2	32
26	Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis. Cells, 2019, 8, 288.	4.1	31
27	Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo. Clinical and Experimental Metastasis, 2008, 25, 611-619.	3.3	29
28	Nuclear hyaluronidase 2 drives alternative splicing of <i>CD44</i> pre-mRNA to determine profibrotic or antifibrotic cell phenotype. Science Signaling, 2017, 10, .	3.6	29
29	Imaging the alternative silencing of FGFR2 exon IIIb in vivo. Rna, 2006, 12, 2073-2079.	3.5	24
30	Translational regulation of human methionine synthase by upstream open reading frames. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2007, 1769, 532-540.	2.4	24
31	Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators. , 2018, 8, 955-979.		24
32	VEGF ₁₆₅ b overexpression restores normal glomerular water permeability in VEGF ₁₆₄ -overexpressing adult mice. American Journal of Physiology - Renal Physiology, 2012, 303, F1026-F1036.	2.7	23
33	SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharmacological Research, 2016, 107, 276-281.	7.1	23
34	Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. Advances in Clinical Chemistry, 2019, 88, 1-33.	3.7	21
35	Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer. British Journal of Cancer, 2020, 123, 1024-1032.	6.4	16
36	CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports, 2021, 11, 7963.	3.3	16

SEBASTIAN OLTEAN

#	Article	IF	CITATIONS
37	Alternative Splicing in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 1596-1603.	6.1	15
38	VEGFâ€A ₁₆₅ b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGFâ€A splice isoforms from the kidney. Journal of Physiology, 2017, 595, 6281-6298.	2.9	15
39	Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease. Genes, 2018, 9, 98.	2.4	15
40	A Runaway PRH/HHEX-Notch3–Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition. Cancer Research, 2020, 80, 757-770.	0.9	13
41	Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Avenues. BioMed Research International, 2017, 2017, 1-1.	1.9	11
42	Familial phosphoglycerate kinase deficiency associated with rhabdomyolysis and acute renal failure: abnormality in mRNA splicing?. Nephrology Dialysis Transplantation, 2003, 18, 445-446.	0.7	9
43	The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy. PLoS ONE, 2019, 14, e0212910.	2.5	7
44	Assessment of Kidney Function in Mouse Models of Glomerular Disease. Journal of Visualized Experiments, 2018, , .	0.3	6
45	The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties. Translational Oncology, 2019, 12, 134-142.	3.7	6
46	Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios. American Journal of Cancer Research, 2015, 5, 2083-9.	1.4	6
47	Vascular Endothelial Growth Factor-A ₁₆₅ b Restores Normal Glomerular Water Permeability in a Diphtheria-Toxin Mouse Model of Glomerular Injury. Nephron, 2018, 139, 51-62.	1.8	5
48	A drug-repositioning screen using splicing-sensitive fluorescent reporters identifies novel modulators of VEGF-A splicing with anti-angiogenic properties. Oncogenesis, 2021, 10, 36.	4.9	5
49	Modulators of alternative splicing as novel therapeutics in cancer. World Journal of Clinical Oncology, 2015, 6, 92.	2.3	5
50	The epithelial splicing regulator <i>ESRP2</i> is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor. Molecular Oncology, 2022, 16, 630-647.	4.6	3
51	A repositioning screen using an FGFR2 splicing reporter reveals compounds that regulate epithelial-mesenchymal transitions and inhibit growth of prostate cancer xenografts. Molecular Therapy - Methods and Clinical Development, 2022, 25, 147-157.	4.1	3
52	Abstract 2749: SRPK1 inhibition and modulation of VEGF alternative splicing as a potential therapeutic strategy in prostate cancer. , 2014, , .		0